First Choice Healthcare Solutions (OTCQB:FCHS), a company focused on building a network of localized, integrated healthcare systems consisting of non-physician-owned medical centers of excellence, joined Executive Casts last year to expound on the business on a level beyond what shareholders will receive from regularly scheduled conference calls. Chris Romandetti, the Company’s CEO, touched upon a […]
First Choice Healthcare Solutions (OTCQB:FCHS) CEO Chris Romandetti had a chance to sit down with Executive Casts to elaborate on important aspects of his company. The four segments highlighted in this post are the first of many that are going to be featured over the next several months so that you will have a chance […]
We read 10K’s so you don’t have to.
Reading one the other day we found a manufacturer that appears to be getting closer to resolve regulatory issues hanging over them and causing doubt.
Then in an interview the CEO casually mentioned a partnership. With a multi-billion dollar multinational, to do distribution.
How much would this information be worth to you?
By: Jay Thompson of SkyTides Inc., with significant support from various experts. The Spectranetics Corporation (NMS:SPNC), a medical devices manufacturer, is up 150%+ and about $750M in market capitalization on hype of its new product, Stellarex. Before getting into Stellarex itself, we want to point out that SPNC management are currently accused of various securities […]
Last Thursday, April 13, 2017, we published our findings on why we are very bearish on Great Basin Scientific (OTC:GBSN) (GBSND), a company that describes itself as a molecular diagnostics company. We commented on what we perceive as a series of bad financings for common stockholders, and why we think the company will once more see its […]
Summary Recently disclosed court documents show that Sinovac Biotech’s (NASDAQ: SVA) CEO bribed a member of the Chinese Food and Drug Administration to assist its vaccine clinical trial and approval Bribery is a clear violation of Foreign Corrupt Practices Act (FCPA) regulations and is prohibited for SEC registered companies like SVA; it could lead to […]
Shares of Repro Med (OOTC:REPR) are little changed following the company’s 2016 second quarter results. We view this as an encouraging sign that the market may finally be ready to shrug off the lingering issue of the FDA Warning letter that we opined upon since April of 2016. While we would not be surprised if shares of […]
By Christopher Irons for GeoInvesting Mallinckrodt’s Acthar Gel may turn out to be the most appalling story in all of price gouging and it has gone completely unnoticed by politicians and the main stream media Price of the drug has gone from $40 per vial in 2001 to $28,000, an over 70,000% increase A good […]